Transcranial direct current stimulation (tDCS) in the management of epilepsy: A systematic review
•TDCS is a non-invasive brain stimulation technique that induces changes in cortical excitability.•This Review encompassed human tDCS trials in epilepsy that reported either seizure frequency or related surrogate outcomes.•Preliminary evidence suggests that cathodal tDCS may lead to better seizure c...
Gespeichert in:
Veröffentlicht in: | Seizure (London, England) England), 2021-03, Vol.86, p.85-95 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •TDCS is a non-invasive brain stimulation technique that induces changes in cortical excitability.•This Review encompassed human tDCS trials in epilepsy that reported either seizure frequency or related surrogate outcomes.•Preliminary evidence suggests that cathodal tDCS may lead to better seizure control in drug-resistant focal epilepsy.•Cathodal tDCS is overall safe and not directly associated with seizures in adults and children with drug-resistant epilepsy.
Current therapies for the management of epilepsy are still suboptimal for several patients due to inefficacy, major adverse events, and unavailability. Transcranial direct current stimulation (tDCS), an emergent non-invasive neuromodulation technique, has been tested in epilepsy samples over the past two decades to reduce either seizure frequency or electroencephalogram (EEG) epileptiform discharges.
A systematic review was performed in accordance with PRISMA guidelines (PROSPERO record CRD42020160292). A thorough electronic search was completed in MEDLINE, EMBASE, CENTRAL and Scopus databases for trials that applied tDCS interventions to children and adults with epilepsy of any cause, from inception to April 30, 2020.
Twenty-seven studies fulfilled eligibility criteria, including nine sham-controlled and 18 uncontrolled trials or case reports/series. Samples consisted mainly of drug-resistant focal epilepsy patients that received cathodal tDCS stimulation targeted at the site with maximal EEG abnormalities. At follow-up, 84 % (21/25) of the included studies reported a reduction in seizure frequency and in 43 % (6/14) a decline in EEG epileptiform discharge rate was observed. No serious adverse events were reported.
Cathodal tDCS is both a safe and probably effective technique for seizure control in patients with drug-resistant focal epilepsy. However, published trials are heterogeneous regarding samples and methodology. More and larger sham-controlled randomized trials are needed, preferably with mechanistic informed stimulation protocols, to further advance tDCS therapy in the management of epilepsy. |
---|---|
ISSN: | 1059-1311 1532-2688 |
DOI: | 10.1016/j.seizure.2021.01.020 |